NEUCA S.A. (7HD) Price & Analysis

0 Followers

7HD Stock Chart & Stats

€195.00

-€0.70(-0.35%)

At close: Jan 08 4:00 PM EST

€195.00

-€0.70(-0.35%)

Day’s Range― - ―

52-Week Range€147.80 - €199.80

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€791.58M

Enterprise Value€4.04K

Total Cash (Recent Filing)€185.27M

Total Debt (Recent Filing)€911.51M

Price to Earnings (P/E)19.2

Beta0.27

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)38.56

Shares Outstanding4,642,802

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-31.55

Price to Book (P/B)3.49

Price to Sales (P/S)0.27

P/FCF Ratio9.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)10.59

Revenue Forecast (FY)€3.36B

Bulls Say, Bears Say

Bulls Say

Stable MarginsStable margins indicate effective cost management and pricing strategies, supporting NEUCA's profitability and operational efficiency over time.

Market PositionAs a market leader in pharmaceutical distribution, NEUCA benefits from established relationships and a strong reputation, providing a durable competitive advantage.

Revenue GrowthConsistent revenue growth showcases NEUCA's ability to maintain its market position and adapt to industry demands, ensuring long-term business sustainability.

Bears Say

Earnings GrowthNegative EPS growth reflects challenges in maintaining earnings momentum, which could impact NEUCA's ability to reinvest in its business and sustain shareholder returns.

Profitability DeclineA decline in profitability metrics like ROE may indicate challenges in generating returns from equity, potentially affecting investor confidence and future growth.

Cash Flow ManagementWeak cash flow management can limit NEUCA's ability to invest in growth opportunities and meet financial obligations, posing a risk to long-term liquidity.

7HD FAQ

What was NEUCA S.A.’s price range in the past 12 months?

NEUCA S.A. lowest stock price was €147.80 and its highest was €199.80 in the past 12 months.

What is NEUCA S.A.’s market cap?

NEUCA S.A.’s market cap is €791.58M.

When is NEUCA S.A.’s upcoming earnings report date?

NEUCA S.A.’s upcoming earnings report date is Aug 27, 2026 which is in 30 days.

How were NEUCA S.A.’s earnings last quarter?

NEUCA S.A. released its earnings results on May 21, 2026. The company reported €3.456 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NEUCA S.A. overvalued?

According to Wall Street analysts NEUCA S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NEUCA S.A. pay dividends?

NEUCA S.A. does not currently pay dividends.

What is NEUCA S.A.’s EPS estimate?

NEUCA S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NEUCA S.A. have?

NEUCA S.A. has 4,642,802 shares outstanding.

What happened to NEUCA S.A.’s price movement after its last earnings report?

NEUCA S.A. reported an EPS of €3.456 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.241%.

Which hedge fund is a major shareholder of NEUCA S.A.?

Currently, no hedge funds are holding shares in DE:7HD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NEUCA S.A.

NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribution, the development and marketing of proprietary drug brands, and a comprehensive healthcare services division. This healthcare arm specifically encompasses outpatient care, clinical trials, and telemedicine. Beyond these core areas, NEUCA S.A. provides an extensive array of additional services, including marketing and advertising support, agency functions, financial solutions, logistics through road cargo transport, accounting and bookkeeping, software development, information technology support, and specialized services for hospitals. The company also offers various insurance products—covering health, property, and other personal lines—and operates its own network of medical supply stores. Established in 1990 as Torfarm SA, the company rebranded to NEUCA S.A. in April 2010.